Abstracts tagged "Biomarkers"

Abstract Number: 1876 • ACR Convergence 2020
The Role of HLA B27 in Axial Spondyloarthritis: Prevalence and Performance as a Marker in an Argentinian Cohort
Rodrigo Garcia Salinas¹, Santiago Ruta¹, Einer Sanchez Prado¹, Jessica Torres Chichande¹, Alvaro Ruta¹, Facundo Salvatori¹ and Sebastian Magri¹, ¹Hospital Italiano La Plata, La Plata, Argentina
Background/Purpose: HLA B27 prevalence in Latin America are heterogeneous and timeless, we propose to estimate the prevalence of HLA B27 in an Argentinian cohort of…
Abstract Number: 0387 • ACR Convergence 2020
Altered Iron Homeostasis and Pulmonary Haemodynamics in Systemic Sclerosis Associated Pulmonary Arterial Hypertension
Alper Sari¹, Christopher Denton², Svetlana Nihtyanova³, Benjamin Schreiber⁴ and Voon Ong³, ¹Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey, ²University College London, London, United Kingdom, ³Centre for Rheumatology, Royal Free Campus, UCL Division of Medicine, UK, London, United Kingdom, ⁴UCL, London, United Kingdom
Background/Purpose: Iron deficiency (ID) is more frequent in systemic sclerosis (SSc) patients with pulmonary hypertension (PH) than those without and associated with worse prognosis. There…
Abstract Number: 0746 • ACR Convergence 2020
HDL-bound yRNA-derived Small RNAs Are Altered in Patients with Rheumatoid Arthritis
Qiong Wu¹, Quanhu Sheng¹, Joseph Solus¹, Danielle Michell¹, Kasey Vickers¹, Ryan Allen¹, C. Michael Stein¹ and Michelle Ormseth¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Small RNAs (sRNAs), including microRNAs (miRNAs) and yRNA-derived sRNAs (yDRs), are important gene regulators and markers of disease. HDL, while known for its anti-atherogenic…
Abstract Number: 0936 • ACR Convergence 2020
Urine Proteomics and Single Cell Transcriptomics Identify IL-16 as a Biomarker for Lupus Nephritis
Andrea Fava¹, Jill Buyon², Chandra Mohan³, Ting Zhang³, H. Michael Belmont⁴, Peter Izmirly⁵, Robert Clancy⁶, Jose Monroy-Trujillo⁷, Celine Berthier⁸, Anne Davidson⁹, Nir Hacohen¹⁰, David Wofsy¹¹, Deepak Rao¹², Soumya Raychaudhuri¹³, The Accelerating Medicines Partnership in SLE Network¹⁴, William Apruzzese¹⁵ and Michelle Petri¹⁶, ¹Johns Hopkins University, Baltimore, MD, ²Department of Medicine, NYU School of Medicine, New York, NY, ³UT Houston, Houston, ⁴New York University, New York, NY, ⁵Department of Medicine, New York University School of Medicine, New York, NY, ⁶NYU School of Medicine, New York, ⁷Johns Hopkins University, Baltimore, ⁸University of Michigan, Ann Arbor, ⁹Northwell Health, New York, ¹⁰Broad Institute, Boston, ¹¹University of California San Francisco, San Francisco, CA, ¹²Brigham and Women's Hospital, Boston, MA, ¹³Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁴Multiple Institutions, Multiple Cities, ¹⁵., Boston, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Treatment of lupus nephritis relies on renal histopathological features. However, renal biopsies do not capture patient-specific active biological pathways. Urine proteomic biomarkers could revolutionize…
Abstract Number: 1197 • ACR Convergence 2020
Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review
Dawson Shaver¹, Daniel Van Kalsbeek¹, Ariadne Ebel¹, Daniel Hershberger¹, Cynthia Schmidt¹, Jill Poole¹, Geoffrey Thiele¹, Dana Ascherman², Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is among the most frequent and severe extra-articular manifestations of RA, contributing significantly to the excess mortality among RA…
Abstract Number: 1464 • ACR Convergence 2020
Multi-Variate Approach Including Serology and Genetics for an Improved Identification of Patients at Risk of Developing Rheumatoid Arthritis
Céline Lamacchia¹, Maresa Grundhuber², Isabel Gehring², Pascale Roux Lombard³, Michael John Nissen¹, Andrea Rubbert Roth⁴, Ruediger Mueller⁵, Ulrich Walker⁶, Burkhard Moeller⁷, Diego Kyburz⁸, Adrian Ciurea⁹, Sascha Swiniarski¹⁰ and Axel Finckh¹¹, ¹Geneva University Hospital, Geneva - 14, Switzerland, ²Thermo Fisher Scientific Phadia GmbH, Freiburg, Germany, ³Geneva University Hospital, Geneva, Switzerland, ⁴Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, ⁵KSA: Aarau Hospital, Aarau, Switzerland, ⁶Basel University Hospital, Basel, Switzerland, ⁷Inselspital - University Hospital Bern, Bern, Switzerland, ⁸University Hospital Basel, Basel, Switzerland, ⁹University Hospital Zurich, Zurich, Switzerland, ¹⁰Phadia GmbH / Thermo Fisher Scientific, Freiburg, Germany, ¹¹Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland
Background/Purpose: First-degree relatives of RA patients (FDR-RA) have an increased prevalence for rheumatoid arthritis (RA) [1] and joint symptoms [2]. Identification of individuals with imminent RA…
Abstract Number: 1791 • ACR Convergence 2020
Renal Tubular Complement C9 Deposition Is Associated with Renal Tubular Damage and Fibrosis in Lupus Nephritis
Shudan Wang¹, Ming Wu², Luis Chiriboga², Beatrice Goilav³, Shuwei Wang⁴, Chaim Putterman⁵, Daniel Schwartz⁶, James Pullman⁶, Anna Broder⁷ and H. Michael Belmont⁸, ¹Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, ²NYU Langone Health, New York, ³The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁴Morristown Medical Center, Morristown, NJ, ⁵Albert Einstein College of Medicine, Bronx, NY, ⁶Montefiore Medical Center, Bronx, NY, ⁷Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ⁸New York University, New York, NY
Background/Purpose: Tubulointerstitial damage in lupus nephritis (LN) is a strong predictor of progression to chronic kidney disease (CKD) and end stage renal disease (ESRD). While…
Abstract Number: 1906 • ACR Convergence 2020
Hsp90 Inhibition Effectively Prevents Progression of Dermal Fibrosis and Induces Regression of Established Bleomycin-Induced Dermal Fibrosis
Hana Storkanova¹, Lenka Storkanova², Sabina Oreska³, Maja Spiritovic⁴, Barbora Hermankova⁵, Radim Becvar¹, Karel Pavelka⁶, Jiří Vencovský⁶, Jörg HW Distler⁷, Ladislav Šenolt⁶ and Michal Tomcik¹, ¹Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha 2, Czech Republic, ⁴Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic,, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁷University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Our previous study demonstrated that Heat shock protein 90 (Hsp90) is overexpressed in the skin of patients with systemic sclerosis (SSc), in cultured SSc…
Abstract Number: 0399 • ACR Convergence 2020
A Heavy Burden of Calcinosis Reflects Cumulative Disease Damage in Scleroderma
Carrie Richardson¹, Jamie Perin², Scott Zeger³, Fredrick Wigley⁴, Laura Hummers⁵, Livia Casciola-Rosen⁶, Antony Rosen⁷ and Ami Shah⁸, ¹Rush University Medical Center, Chicago, IL, ²JHUSPH, Baltimore, ³Johns Hopkins University, Baltimore, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Johns Hopkins Univerisity, Ellicott City, MD, ⁶Johns Hopkins University, Johns Hopkins University, MD, ⁷Johns Hopkins University, Baltimore, MD, ⁸Johns Hopkins University School of Medicine, Ellicott City, MD
Background/Purpose: Ectopic calcification, or calcinosis, is a common complication of scleroderma. However, a subset of scleroderma patients has a heavy burden of calcinosis, which may…
Abstract Number: 0747 • ACR Convergence 2020
Isotope-Labeling-LC-MS-based Metabolic Profiling of Multiple Serum Sample Sets for the Discovery of High-confidence Rheumatoid Arthritis Biomarkers
Xiaohang Wang¹, Wei Han¹, Liang Li¹, Stephanie Wichuk², Edna Hutchings³, Rana Dadashova³, Joel Paschke³ and Walter Maksymowych², ¹Department of Chemistry, University of Alberta, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) is hampered by suboptimal accuracy of currently available serological biomarkers. In this work, we applied a high-performance chemical…
Abstract Number: 1061 • ACR Convergence 2020
Daily Myositis Symptom Changes Collected via a Smartphone-Based App Are Associated with Flare Occurrence – Providing Evidence of Potential Digital Biomarkers
Alexander Oldroyd¹, Belay Yimer², Max Little³, William Dixon² and Hector Chinoy⁴, ¹University of Manchester, Manchester, United Kingdom, ²Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom, ³University of Birmingham, Birmingham, United Kingdom, ⁴The University of Manchester, Manchester, United Kingdom
Background/Purpose: The concept of idiopathic inflammatory myopathy (IIM) flare is widely used, although no consensus definition exists. Studies have demonstrated the feasibility and utility of…
Abstract Number: 1204 • ACR Convergence 2020
Use of Multi-Biomarker Disease Activity Scores to Assess Biosimilarity in a Phase 3 Randomized Controlled Trial Comparing Biosimilar Infliximab-qbtx (PF‑06438179/GP1111) with EU-Sourced Reference Infliximab in Patients with Active RA
Jonathan Kay¹, Daniel Alvarez², Muhammad Iftikharur Rehman³, Min Zhang⁴ and Noriko Iikuni⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Pfizer, Collegeville, PA, ³Pfizer, Andover, MA, ⁴Pfizer, La Jolla, CA, ⁵Pfizer, New York, NY
Background/Purpose: The multi-biomarker disease activity (MBDA; Vectra® DA, Myriad Genetics, Inc.) score is calculated from concentrations of 12 serum proteins to assess disease activity (DA)…
Abstract Number: 1510 • ACR Convergence 2020
Platelet-bound C4d Is Associated with Platelet Activation and Arterial Thrombotic Events
Yevgeniya Gartshteyn¹, Adam Mor², Daichi Shimbo², Leila Khalili³, Teja Kapoor⁴, Laura Geraldino-Pardilla⁵, Roberta Vezza Alexander⁶, Thierry Dervieux⁷ and Anca Askanase², ¹Columbia University College of Physicians and Surgeons, Glen Rock, NJ, ²Columbia University College of Physicians and Surgeons, New York, NY, ³Columbia University Medical Center, New Haven, CT, ⁴Columbia University College of Physicians and Surgeons, Leonia, NJ, ⁵Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, ⁶Exagen Inc, Vista, CA, ⁷Prometheus Biosciences Inc, Irvine, CA
Background/Purpose: Platelets have a well-defined role in arterial thrombosis, and platelet-bound complement activation products (PC4d) correlate with vascular thromboses in patients with Systemic Lupus Erythematosus…
Abstract Number: 1792 • ACR Convergence 2020
Platelet-bound C4d Is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE
Yevgeniya Gartshteyn¹, Roberta Vezza Alexander², John Conklin³, Thierry Dervieux⁴ and Anca Askanase⁵, ¹Columbia University College of Physicians and Surgeons, Glen Rock, NJ, ²Exagen Inc, Vista, CA, ³Exagen Inc., Vista, CA, ⁴Prometheus Biosciences Inc, San Diego, CA, ⁵Columbia University College of Physicians and Surgeons, New York, NY
Background/Purpose: Platelet-bound complement activation products (PC4d), defined as PC4d20 net mean fluorescent intensity [MFI], or a thrombotic risk score that includes PC4d, C3 and anti-phosphatidylserine/prothrombin…
Abstract Number: 1922 • ACR Convergence 2020
Association of Leukocyte Populations in Peripheral Blood and Arterial Wall Inflammation Assessed by FDG-PET in Takayasu’s Arteritis and Giant Cell Arteritis
K. Bates Gribbons¹, Kaitlin Quinn², Mark Ahlman³, Peter Merkel⁴ and Peter C. Grayson⁵, ¹McGovern Medical School UT Houston, Houston, TX, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Positron emission tomography (PET) is useful to demonstrate fluorodeoxyglucose (FDG) uptake in the large arteries in both Takayasu’s arteritis (TAK) and giant cell arteritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].